feburic中文的说明书

Feburic was approved for marketing in the United States in 2009. It is a new generation of xanthine oxidase inhibitor developed by Teijin Company of Japan. It has obvious advantages in the treatment of gout. It was approved to be launched in the Chinese market by the State Food and Drug Administration on September 4, 2018. Before using a new drug, we need to carefully read the drug's instructions. The following is the Chinese instruction manual of feburic compiled by Medical Companion Travel. I hope it will be helpful to you.

Drug name: Febuxostat

Other names: Febuxostat, feburic

Main ingredient: febuzotostat, chemical name is 2-[(3-cyano-4-isobutoxy)phenyl]-4-methyl-5-thiazolecarboxylic acid.

Indications: feburic is mainly used for the long-term treatment of hyperuricemia with gout symptoms. However, it is not recommended for patients with asymptomatic hyperuricemia.

Usage and dosage: Normally, the initial recommended dose for patients is 40 mg/day, administered orally. If the symptoms are severe, it can be adjusted to 80 mg/day; if the serum uric acid level is still higher than 6 mg/dL after 2 weeks of taking 40 mg/day, the dose can be increased to 80 mg/day.

Dose adjustment: No dosage adjustment is required for patients with mild to moderate (CrCl 30-89 mL/min) renal impairment; the dosage for patients with severe (CrCl <30 mL/min) should not exceed 40 mg/day. No dose adjustment is required for patients with mild to moderate (Child-Pugh Class A or B) hepatic impairment; there are no trial data for patients with severe (Child-Pugh Class C) hepatic impairment and should be used with caution.

Adverse reactions: Common adverse reactions when using feburic include abnormal liver function, joint pain, nausea, rash, diarrhea and dizziness. Other adverse reactions include upper respiratory tract infection, lung infection, edema, headache, muscle and skeletal muscle and related tissue abnormalities, abnormal sensation and insensitiveness.

Serious adverse reactions are cardiovascular diseases, including non-fatal myocardial infarction, non-fatal stroke and cardiovascular death. The incidence is higher than that of allopurinol. The incidence of cardiovascular adverse reactions is not related to the dose of feburic and does not increase with the extension of treatment time.